Study on tremor peak frequency, power and harmonics between Parkinson's disease and multiple system atrophy-parkinsonism / 中华神经科杂志

ABSTRACT

Objective To summarize the characteristics of tremor peak frequency,power and harmonics occurrence rate between Parkinson's disease (PD) and multiple system atrophy-parkinsonism (MSA-P).Methods From January to December in 2016,48 PD patients and 22 MSA-P patients were enrolled in Beijing Tiantan Hospital.Upper limb tremor patients got tremor analysis test in rest,posture and holding 1 000 g states,while lower limb tremor patients in rest and posture states.Peak frequency,power and harmonics occurrence rate of tremor were compared between PD and MSA-P patients in different states.Results Peak frequency of PD and MSA-P patients in upper rest ((4.76± 0.82) Hz vs (6.03 ± 0.25)Hz,t=-2.161,P=0.037),posture ((5.25 ±0.88) Hz vs (7.66 ±1.90) Hz,t=-4.266,P=0.001),holding 1 000 g ((5.80 ± 1.28) Hz vs (8.32 ± 1.51) Hz,t =-6.436,P =0.000) and lower posture ((4.85 ±0.78) Hz vs (6.42 ± 1.13) Hz,t =-3.001,P =0.012) showed statistically significant difference.Half-width power of PD and MSA-P patients in upper rest (extensor15.70 (5.82,32.96)mg2/μV2 vs 3.14 (1.69,4.60) mg2/μV2,Z =-2.008,P =0.037),in posture (extensor33.14(20.46,64.27) mg2/μV2 vs 10.02 (7.11,14.60) mg2/μV2,Z =-3.627,P =0.000;flexor27.49(9.48,41.74) mg2/μV2 vs 5.97 (4.41,15.59) mg2/μV2,Z =-2.336,P =0.019),in holding 1 000g (flexor17.80 (9.40,36.60) mg2/μV2vs8.15 (5.32,17.65) mg2/μV2,Z=-2.494,P=0.013),and in lower posture (flexor26.63(7.09,85.84) mg2/μV2 vs 3.78 (2.51,7.12) mg2/μμV2,Z=-2.049,P =0.045) showed statistically significant difference.Harmonics occurrence rate of PD and MSAP patients in rest (82.5％ vs 5.9％,χ2 =29.096,P =0.000),posture (80.0％ vs 5.9％,χ2 =26.884,P=0.000) and holding 1 000 g (65.0％ vs 0,χ2 =20.318,P=0.000) had statistically significant difference.Conclusions Tremor peak frequency in PD patients was lower than that in MSA-P patients,while power and harmonics occurrence rate in PD patients were higher than in MSA-P patients.